Meeting
2013 Genitourinary Cancers Symposium
Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment.
Authors
Maristella Bianconi
Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy
Maristella Bianconi , Mario Scartozzi , Luca Faloppi , Cristian Loretelli , Antonio Zizzi , Riccardo Giampieri , Alessandro Bittoni , Michela Del Prete , Luciano Burattini , Rodolfo Montironi , Stefano Cascinu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 388)
DOI
10.1200/jco.2013.31.6_suppl.388
Abstract #
388
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib.
First Author: Maristella Bianconi
Poster
2023 ASCO Genitourinary Cancers Symposium
Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.
First Author: Chris Labaki
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst